KPV Research Peptide: An Overview of the Anti-Inflammatory Tripeptide

KPV is a synthetic tripeptide composed of lysine, proline, and valine (Lys-Pro-Val) and represents the carboxyl-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). First identified in inflammation research, KPV has drawn ongoing attention from preclinical investigators studying anti-inflammatory signaling, mucosal biology, and skin research models.

Note: All content on this page is intended strictly for research and educational purposes. KPV is a research compound and is not approved for human use by the FDA or any regulatory authority.

Origin and Structure

α-MSH is a 13-amino-acid peptide derived from proopiomelanocortin (POMC) processing. Investigators noted in the 1990s that much of α-MSH’s anti-inflammatory activity could be reproduced by its smaller C-terminal fragment, KPV. Because the tripeptide retains a meaningful share of the parent molecule’s biological signature while being far simpler to synthesize and far more stable in solution, KPV became a useful pharmacological probe for studying the non-melanocortin-receptor pathways through which α-MSH appears to exert inflammation-related effects.

Proposed Mechanisms of Action

Preclinical literature has explored several converging mechanisms by which KPV may modulate inflammatory signaling in cell and animal models:

• NF-κB pathway modulation: Multiple in vitro studies report that KPV reduces nuclear translocation of NF-κB in stimulated immune cells, lowering downstream transcription of pro-inflammatory cytokines.
• Cytokine attenuation: Cell culture work has observed reductions in IL-6, IL-8, and TNF-α release following KPV exposure in challenged epithelial and immune cell lines.
• Intracellular delivery via PepT1: Research published in the Journal of Clinical Investigation has demonstrated that KPV can enter intestinal epithelial cells via the PepT1 oligopeptide transporter, providing a plausible route by which oral or topical formulations might reach intracellular targets in mucosal research models.
• Melanocortin-independent activity: Unlike full-length α-MSH, KPV does not appear to require classical melanocortin receptor binding for its observed anti-inflammatory effects, which has made it of interest to investigators studying receptor-independent inflammation modulation.

Areas of Research Interest

KPV has appeared across several preclinical research areas. None of the work below constitutes a medical indication or a recommendation for human use — these are research contexts in which the peptide has been studied:

• Intestinal inflammation models: Rodent colitis models have been used to study KPV’s effect on epithelial inflammation markers and barrier function.
• Dermatological research: Skin and wound research has examined KPV in irritation, allergic contact, and acne-pathogen co-culture models.
• Ocular inflammation models: Some preclinical work has explored topical KPV in models of ocular surface inflammation.
• Mast-cell biology: KPV has been used as a tool compound for probing mast-cell activation and degranulation pathways in vitro.

Stability and Handling in the Lab

As a short, charged tripeptide, KPV is more chemically stable than its parent α-MSH but still benefits from careful handling. Lyophilized KPV is typically stored at -20°C protected from light and humidity. Once reconstituted in sterile, peptide-grade solvent, working solutions are commonly stored at 2–8°C and used within a research-protocol-defined window. Investigators working with KPV in cell culture often pre-screen excipient compatibility, as the tripeptide’s small size makes it sensitive to surfactant and carrier interactions.

Why Researchers Use KPV

Investigators often select KPV when they need a small, well-characterized tool compound for probing NF-κB-driven inflammation in cell and tissue models. Its small size, oral and topical bioavailability in animal models, and decades of accumulated preclinical literature make it useful for comparative pharmacology, mechanistic dissection, and as a positive-control compound in inflammation assays.

Regulatory and Research-Use Status

KPV is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any condition in humans. It is offered strictly as a research-grade compound for laboratory investigation. Material provided by Avenio Bio is intended only for qualified researchers working within institutional safety, ethics, and regulatory frameworks. See our KPV product page for material specifications, batch documentation status, and lab handling notes.

Disclaimer: This article is for informational and educational use within a research context. Avenio Bio products are intended strictly for laboratory and research purposes. Not for human consumption.